The ability of Sn(tin)-protoporphyrin to inhibit the induction of hepatic 5-aminolevulinate (ALA) synthase by allylisopropyl acetamide (AIA) was examined in the adult rat. Doses of Snprotoporphyrin of 1, 10, and 50 ;tmol/kg body wt resulted in decreases in AIA-induced hepatic ALA-synthase activity of 32, 52, and 60%, respectively, compared with rats treated with AIA alone; inhibition of ALA-synthase was not a direct effect of Snprotoporphyrin. This inhibition of the enzyme activity in liver was reflected in concurrent decreases in urinary excretion of ALA and porphobilinogen (PBG). The increased urinary excretion of ALA and PBG observed following AIA treatment was reduced by the lowest dose of Sn-protoporphyrin (1 gmol/kg body wt) and abolished completely by the higher doses of the metalloporphyrin (10 and 50 gmol/kg body wt). These findings in a rat model of hepatic porphyria suggest that Sn-protoporphyrin may be useful in the treatment of acute exacerbations of "inducible" hepatic porphyrias in man, especially since Sn-protoporphyrin, unlike hematin which is presently used for this purpose, is neither degraded by nor induces the activity of heme oxygenase.
Introduction
The porphyrias comprise a group of diseases each of which is characterized by a specific genetically determined defect of one of the enzymes of the heme biosynthetic pathway (1) . While the defect is usually inherited, the internal milieu, especially the hormonal and nutritional status ofthe individual, is a vital factor in the clinical expression of the genetic defect in forms of the disease such as acute intermittent porphyria. Clinical expression of the disease is almost invariably accompanied by the accumulation of those products of heme biosynthesis generated proximal to the defective enzyme (1, 2) . The first and rate-limiting enzyme in heme synthesis is mitochondrial 6-aminolevulinic acid (ALA)' synthase which catalyzes the condensation of glycine with succinyl-CoA to form ALA (3). In the "inducible" forms of hepatic porphyria (AIP, hereditary coproporphyria, and Receivedfor publication 7 August 1985. 1. Abbreviations used in this paper: AIA, allylisopropyl acetamide; ALA, 6-aminolevulinic acid; PBG, porphobilinogen. variegate porphyria), treatment of an acute attack is directed toward suppression of ALA-synthase and the effectiveness of therapy is monitored by measuring porphyrin precursor excretion and by clinical status (1, 2) . Many therapeutic approaches have been applied to these diseases but only two clinical strategies are widely accepted: high carbohydrate loading (4-6), and intravenous hematin administration (7) (8) (9) . Recently, we have described a third therapeutic approach, the use of synthetic luteinizing hormone-releasing hormone agonist analogues in those porphyric women who have cyclical attacks of the disease in relation to their menses (10) .
We have previously reported the ability ofthe synthetic heme analogue Sn(tin)-protoporphyrin to suppress the activity of heme oxygenase and decrease bilirubin production and hyperbilirubinemia in animals and humans ( I1-1 5). Sn-protoporphyrin administration has also been shown to result in a rapid (within 60 min), nearly complete, heme saturation of rat hepatic tryptophan pyrrolase ( 16), which strongly suggests that some fraction of functional hepatic heme content is transiently increased following administration of the compound. We hypothesized that Sn-protoporphyrin might inhibit ALA-synthase and porphyrin precursor accumulation. This report describes our studies to test this hypothesis in a rat model of porphyria in which ALA-synthase is induced after the destruction of endogenous heme by allylisopropyl acetamide (AIA) (17) (18) (19) . The results ofthis study indicate that Sn-protoporphyrin is highly effective in suppressing AIA-induced hepatic porphyria in the rat.
Methods
Male Sprague-Dawley rats (150-200 g), purchased from Taconic Farms Inc., Germantown, NY, were maintained in metabolic cages at 220C on a 12:12-h light/dark cycle with free access to powdered rat chow and water. After a minimum of 5 d acclimatization to the cages, animals were injected subcutaneously with saline, Sn-protoporphyrin, and/or AIA at the doses indicated in the legends to figures. During experiments, urine was collected in light-shielded containers and frozen at -200C until assay. Tissue preparation and measurement of mitochondrial ALAsynthase activity and protein were carried out as previously described (20, 21) . Urinary ALA and porphobilinogen (PBG) were measured as described (22) using modified Ehrlich's reagent (23) , and the results were expressed as micrograms per 24 h. Sn-protoporphyrin concentrations in urine were measured fluorometrically by the method of Simionatto et al. (24) . Differences between means were examined by the t test. protoporphyrin (w, 10 ,mol/kg body wt; subcutaneously). Animals were treated at 0 h and killed at the indicated times. Means± SEM are presented; n = 3, *P < 0.05, ***P < 0.01 compared with respective AIA-treated control. activity in AIA-treated rats. Both induction of the enzyme by AIA and concomitant inhibition of the induction response by Sn-protoporphyrin were detectable at 2 h, maximal at 24 h, and had returned to base-line levels by 48 h. Accordingly we used 24-h time-points in subsequent experiments. The dose response of Sn-protoporphyrin inhibition of AIA-stimulated ALA-synthase activity is shown in Fig. 2 . Doses of Sn-protoporphyrin of 1, 10, and 50 umol/kg body wt led to 32, 52, and 60% decreases, respectively, in ALA-synthase activity compared with AIA treatment alone. Direct addition of Sn-protoporphyrin (250 ,OM) to mitochondria from control or AIA-treated rats was without effect on ALA-synthase activity (data not shown). Means±SEM are presented; n = 3-9. *P < 0.05, **P < 0.02, ***P < 0.01 compared with controls. Additionally, for ALA, at h, Sn-protoporphyrin, 10 umol/kg body wt, was significantly different from 1 gmol/kg body wt (P < 0.05). For PBG, both 0-24 h, and 24-48 h, Sn-protoporphyrin, 10 tmol/kg body wt, was significantly different from 1 gmol/kg body wt (P < 0.05).
line in the 48-72-h period. Sn-protoporphyrin administration resulted in a dose-dependent decrease in the content of ALA and PBG in urine ofAIA-treated rats; 1 umol/kg body wt resulted in an -50% reduction, while 10 Whatever the proximate mechanism of the inhibitory effect of Sn-protoporphyrin on ALA-synthase formation, this compound might be useful in the treatment of acute exacerbations of "inducible" hepatic porphyrias. Unlike hematin, Sn-protoporphyrin is not degraded by heme oxygenase nor does it induce this enzyme, an action which would enhance exogenous and endogenous heme catabolism, and thus attenuate the therapeutic response to hematin. In animal studies, we have observed no overt toxicity with doses ofSn-protoporphyrin greatly exceeding those used in this study and administered at weekly intervals for a period as long as 32 wk (32) . Whether low doses (i.e., -1.0 ,umol/kg body wt) of Sn-protoporphyrin would be as effective in decreasing the enhanced activity of hepatic ALA-synthase in the porphyria patient in crisis as they are in suppressing heme oxygenase activity and hyperbilirubinemia in animals and man (15) is not yet known, but this question is presently under investigation in this laboratory. Finally, other potential advantages of Sn-protoporphyrin are that there is no known in vivo mechanism for the enzymatic degradation of the metalloporphyrin and that the compound persists in tissues for periods of up to 7 d after a single dose (33) . These facts suggest that low doses of Sn-protoporphyrin may prove useful in the treatment of acute attacks of the "inducible" hepatic porphyrias.
